Axicabtagene Ciloleucel in Large B Cell Lymphoma Ineligible for Autologous Stem Cell Transplantation: The Phase II Alycante Trial

Investigators conducted a Phase II study (ALYCANTE) to assess the efficacy and safety of a single axi-cel infusion as a second-line therapy in patients with high-risk relapsed/refractory (R/R) large B cell lymphoma deemed ineligible for ASCT but eligible for CAR-T cell therapy.